CYLD

Across TCGA pan-cancer cohorts, CYLD Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CYLD data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CYLD Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CYLD expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

STAD, LUAD, and ESCA are the cancer types where CYLD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	1.000	0.345	.013	32	view →
LUAD	OS	Median	II,III,IV	0.212	0.755	<.001	28	view →
ESCA	DFS	Median	II,III,IV	0.204	0.528	.011	18	view →
UCEC	DFS	Median	All	0.952	0.825	.012	14	view →
THYM	OS	Median	All	0.593	0.880	.005	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	0.928	0.652	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CYLD–STAD (DFS)

Open the STAD breakdown →